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The alarming rise of morbidity and mortality caused by influenza pandemics and
epidemics has drawn attention worldwide since the last few decades. This life‐
threatening problem necessitates the development of a safe and effective vaccine to
protect against incoming pandemics. The currently available flu vaccines rely on
inactivated viral particles, M2e‐based vaccine, live attenuated influenza vaccine (LAIV)
and virus like particle (VLP). While inactivated vaccines can only induce systemic
humoral responses, LAIV and VLP vaccines stimulate both humoral and cellular immune
responses. Yet, these vaccines have limited protection against newly emerging viral
strains. These strains, however, can be targeted by universal vaccines consisting of con-
served viral proteins such as M2e and capable of inducing cross‐reactive immune
response. The lack of viral genome in VLP and M2e‐based vaccines addresses safety
concern associated with existing attenuated vaccines. With the emergence of new
recombinant viral strains each year, additional effort towards developing improved uni-
versal vaccine is warranted. Besides various types of vaccines, microRNA and exosome‐
based vaccines have been emerged as new types of influenza vaccines which are asso-
ciated with new and effective properties. Hence, development of a new generation of
vaccines could contribute to better treatment of influenza.
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2 of 13 KESHAVARZ ET AL.the two strains of type B. Quadrivalent influenza vaccines were devel-
oped during 2013‐14 influenza season in the United States and con-
tain the same A strains and two strains of influenza B lineages.1
These vaccines have high intrinsic immunogenicity that makes them
effective against pandemic.2,3
International surveillance is performed annually by the World
Health Organization4 to choose appropriate virus strains for inclusion
in seasonal influenza vaccines. These selected strains provide HA and
NA genes for reassortant vaccine viruses, which also possess internal
genes from A/Puerto Rico/8/34 (PR8). PR8 is a strain that confers
high viral yield in embryonated eggs. Formalin or β‐propiolactone is
used to inactivate influenza viruses. Thiomersal or formaldehyde is
used in vaccines as a preservative in order to inhibit bacterial or fungal
growth. Some manufacturers may also use aminoglycoside antibiotics.
Some vaccines contain additives like gelatine to stabilize them in
unfavorable conditions. Residual egg proteins are also present in low
quantities in egg‐derived inactivated vaccines.5,6 Although virus multi-
plication on embryonated chicken eggs remains the most common
method for production of influenza vaccines, it contains several limita-
tions. For instance, securing sufficient qualified eggs for mass vaccine
production of the vaccine is very challenging, especially in context of
influenza outbreak among poultry.7 Furthermore, optimization of
influenza wild type strains for growth in eggs requires recombination
of these strains with high‐yield laboratory strains. Thereupon, muta-
tions in the egg‐adapted reassortant strain can contribute to a mis-
match between the vaccine strain and the circulating strain which
was reported recently.8
Trivalent inactivated vaccination can induce local and systemic
immune responses (Figure 1). Influenza‐specific antibodies including
IgG especially IgG1 (high concentration), IgA, and IgM (low concentra-
tion) are detectable 2 to 6 days post‐vaccination and peak 2 to
3 weeks after vaccination in primed subjects.9-13 Upon vaccination,
antibody production is typically type specific. However, it can be
highly cross‐reactive which results in protection towards earlier and
newer viral strains.14,15
It has been shown that Influenza inactivated vaccines up‐regulate
three activation markers of MHC II (CD40, CD80, and CD86), while
exposure to active virus and subunit (SU) vaccine has a less similarFIGURE 1 Inactive influenza vaccine. Trivalent inactivated vaccines can
virus induced high level production of IFN‐α and inflammatory cytokines s
dependent manner by recognition of viral ssRNA. Signaling of TLR7 in pDC
antibodies especially IgG1 (high concentration), IgA, and IgM (low concentra
SIgA2 are the major antibody response in the oral fluid. Inactivated vaccin
markers of MHC II (CD40, CD80, and CD86); high expression of this mole
antigen presentation process and then high activation of innate and adapteffect on CD86 expression. Studies show that treatment of DCs with
SU vaccines results in similar levels of IL‐6 and TNFα. In contrast, in
influenza attenuated vaccine (AV) and IV‐treated DC cultures, IL‐6
and TNFα levels were clearly increased.16
Live or inactivated influenza virus can induce production of IFN‐α
and inflammatory cytokines from plasmacytoid DC (pDCs) in aToll‐like
receptor (TLR7) and MyD88‐dependent manner by recognition of viral
single‐stranded RNA virus (ssRNA).17 Signaling of TLR7 in pDCs has
an important role in inducing productive antibody response by virion
RNA‐containing split vaccine18 and inactivated whole virus vaccine.19
Conversely, following influenza virus infection in the lungs, cytokine
production did not require TLR7‐signaling in pDCs.20
Similar to live viral vaccines, the live attenuated influenza vaccine
(LAIV) induces the expression of several interferon‐related genes.
Whereas, the TIV vaccine induces a signature composed of genes
highly expressed in plasma B cells. In the case of TIV, there are 44
genes identified to accurately predict the outcome of immunization
as either high or low antibody titres. Of these, the
calcium/calmodulin‐dependent protein kinase IV (CaMKIV) gene
has no known role in regulating immunity, but has a negative
correlation with antibody titres. In agreement with this finding, high
antibody titres were observed in the CAMKIV‐deficient mice after
vaccination.21
There are comprehensive data about safety properties of
inactivated influenza vaccines. Soreness at the vaccination site is a
very common local reaction. These kinds of reactions are self‐limiting
and require no intervention. Systemic reactions such as fever,
headache, myalgia, or any physical unease happen mostly in children
and due to initial exposure to influenza vaccine antigens. These
mild adverse events (AEs) are found within 6 to 12 hours post‐
immunization and last for 1 to 2 days.22 Figure 2 and Table 1 illustrate
various forms of influenza vaccines.2 | LIVE ATTENUATED INFLUENZA VACCINE
Customary live influenza vaccines are usually attenuated by adapting
them to replicate at lower temperatures. These cold adapted virionsinduce innate and adaptive immune responses. Inactivated influenza
uch as IL6, IL1, and TNF‐a from pDCs in a TLR7‐and MyD88‐
s has an important role for inducing productive. Influenza‐specific IgG
tion) produced in primed subjects. SIgA1 with lower concentrations of
ation results in obvious up‐regulation of each of the three activation
cules on antigen presenting cells (ex: DC, MQ) results in increased
ive immune responses.
FIGURE 2 Various forms of influenza vaccine. Application use of the vaccine of the complete influenza virus (LAIV), surface proteins (subunit
vaccine), nucleoproteins (CTL‐based vaccine), viral genomes (DNA vaccine), and inactive viruses (inactivated vaccine) is shown in the figure.
Looking at which distinct types of vaccines, different immunological pathways are induced in innate and adaptive immunity. Finally, the stimulation
of the B lymphocytes and the production of specific antibodies secreting plasma cells.
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influenza A virus. There are additional methods for virus attenuation.
For example, the NS1‐based escape mutants of influenza virus can
be applied to create live‐attenuated influenza viruses by elimination
of NS1 through truncation or deletion of the corresponding gene.23-
25 Another way is modification of viral M1 protein, which can induce
protective humoral and cellular immune responses against homologous
and heterologous influenza viruses in mice.26
Live attenuated vaccination induces both secretory (mucosal
response) and systemic immune responses, which is closely similar to
immune response observed upon natural infection. Previously, in
young children, live AVs were administered by nasal drops27; cur-
rently, this vaccine is administered intranasally. However, immunoge-
nicity between the two approaches is similar. Mucosal response
induced by live attenuated vaccination is characterized by IgA anti-
bodies in nasal secretions, which peak 2 to 11 weeks after vaccination
and slowly decrease by 6 months to 1 year post‐vaccination in
children (Figure 3).28,29
Live attenuated (cold‐adapted) influenza vaccines are likely to
activate TLR3 and ‐7 during viral replication intracellularly leading to
the up‐regulation of inflammatory cytokines, and thus adjuvants are
not needed.30
Studies have shown that influenza virus infection induces the
expression and activation of NLRP3 inflammasome components
(NLRP3, ASC, and Caspase‐1).31 The NLRP3 inflammasome compo-
nents mediate IL‐1β and IL‐18 production in different cell types
in vitro including mice bone marrow dendritic cells (BMDCs) and bone
marrow macrophage (BMMΦ), human macrophage (MΦ), nasal airway
epithelial cells, and monocytic cell line THP‐1.32-35 For this reason, the
NLRP3 inflammasome‐deficient mice did not produce IL‐1β and IL‐18
following the high lethal dose influenza virus infection. Hence, the
reduced protective inflammation including the suppressedaccumulation of neutrophils and monocytes to the lungs and airways
and consequently higher mortality upon influenza virus were observed
in NLRP3‐deficient mice.35
Due to the previously mentioned side effects, it seems that
inactivated influenza vaccines are no longer such safe options for
immunization, and, as a result, researchers are trying to develop alter-
native vaccines such as live AVs and VLPs, which are expected to have
lower adverse effects; however, some studies have reported opposite
results. Higher rate of respiratory AEs and hospitalizations was
observed among children receiving LAIV compared with trivalent
inactivated influenza vaccine recipients.36 A study indicates that
despite of higher rate of AEs like respiratory inflammatory responses
in LAIV vaccinated individuals in comparison with TIV vaccines,
Guillain‐Barre Syndrome and paralysis are significantly more abundant
in TIV recipients.37 Although fever, abdominal pain, and other symp-
toms are reported after LAIV vaccination, it is indicated that overall
various AEs like asthma/wheezing do not increase significantly among
LAIV vaccinated children compared with controls.383 | RECOMBINANT SUBUNIT VACCINES
The use of recombinant SU influenza vaccines can solve the problems
associated with the use of chicken embryos and the urgency to atten-
uate strains of the influenza virus. One of the new methods to the
manufacture of SU influenza vaccines is use of different expression
systems for rapid production of individual viral proteins in preparative
levels. Baculoviral expression systems produced influenza antigens in
insect cells by using baculoviral vectors that transport the genes of
the target antigens. The Autographa californica multiple
nucleopolyhedrovirus (AcMNPV) genome is used in Sf9 cell lines
obtained from Spodoptera frugiperda for production of different
TABLE 1 Advantages and disadvantages of different influenza vaccines
Vaccine Type Advantage Disadvantage
Inactive vaccine a) All age groups (except children under 6 months) with no
contraindications can receive inactivated influenza vaccine
b) Safe in pregnant women
c) Use in immunocompromised patients
a) Soreness at the vaccination site,fever, headache, myalgia,
or any physical unease happen mostly in children
b) Allergy
c) In rare case autoimmune disorders
Live attenuate a) Safe in cystic fibrosis patients
b) No systemic allergic reactions such as urticaria,
angioedema, rhinitis, and eczema
a) Mild to moderate symptoms including runny nose,
sneezing, nasal discomfort, fever and headache
b) Is not recommended to be routinely used in pregnant
women
Recombinant a) High safety profile without involving infectious viruses
b) Rapid, stable
c) Induces humoral and cellular immune responses
a) Low immunogenicity
b) Require appropriate adjuvants
DNA vaccine a) Induce all three arms of adaptive immunity, CTLs,
antibodies, and helper T cells
b) Possible mucosal delivery and thus may stimulate innate
immunity
a) Lower immunogenicity, low level of T‐cell, and B‐cell
memory due to
b) Integration of DNA vaccine genetic material into cellular or
host DNA,
c) Development of autoimmune disorders against host DNA
Universal vaccine M2e:
a) Induces M2e‐specific humoral and cellular immune
responses;
b) Elicits broad cross‐protection against divergent virus
strains
a) Single M2e molecule induces lower immune responses
Epitope‐base:
a) They are considered to be safe, easy to produce, and
stable.
b) Can induce B‐cell and T‐cell in the same formulation
a) The main disadvantage of the epitope‐based vaccine is
that algorithms may fail to predict all the appropriate
epitopes
CTL inducing vaccine a) Target conserved influenza virus proteins and improve
recovery and inhibit disease progression
a) Need to have an epitope that can be recognized by all
major histocompatibility complex (MHC)
RNA vaccine a) Safety
b) Efficacy
c) Higher potency (especially with self‐amplifying RNA
vaccines)
a) Possibility of adverse consequences like thrombus and/or
edema
b) Limited availability in cases of pandemic and endemic
diseases.
FIGURE 3 Live attenuated influenza vaccine. Live attenuated vaccination induces both innate and adaptive immune response. Among all
receptors in the innate immune system, TLRs and NLRs have an important role. Live attenuated influenza vaccines activate TLR3 and 7 leading
to the up‐regulation of inflammatory cytokines. NLRs have a differential role in response to influenza virus infection in order to innate immunity
balance. Expression and activation of NLRP3 inflammasome components (NLRP3, ASC, and Caspase‐1) mediate IL‐1β and IL‐18 production in
different cell types. NLRC2 (or NOD2) recruit MAVS adaptor protein and type I IFN production in DCs and MΦ after recognizes the viral genomic
ssRNA in response to influenza virus. In addition, NLRX1 promotes both MΦ survival as well as type I IFN signaling in mice after binding to viral
protein PB1‐F2. Mucosal response induced by live attenuated vaccination is characterized by IgA antibodies in nasal. Systemic immune response
against live attenuated vaccine characterized by production of IgA and IgM in serum. IgG1 is the major IgG subclass produced by live attenuated
vaccination in the serum.
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recombinant SU vaccine is low immunogenicity; therefore, the need
for repeated vaccination and use of adjuvants are recommended.39,40
As mentioned, use of adjuvants in the composition of SU vaccines
can resolve this problem. The recombinant protein STF2.4 × M2e that
includes flagellin and produced in Escherichia coli cells has protected
mice to a lethal dose of the influenza virus. In another study, safety
and efficacy of a vaccine based on this construct were illustrated in
adult volunteers. Immunization of mice with the recombinant fusion
protein 4 × M2e. HSP70c demonstrates a reduced viral titer in the
lungs, significant decrease in weight loss, and a less pronounced man-
ifestation of the symptoms of the disease after challenge mice groups
with a lethal dose of the influenza A H1N1, H3N2, or H9N2 viruses.41
The most favorable candidate for influenza SU vaccines is M2 pro-
tein (the ion channel‐forming protein). M2 is a highly conserved protein
expressed on the virion's surface. The M2 protein ectodomain (M2e) is
regarded as a candidate for designing broad‐spectrum vaccines. Because
of low immunogenicity, using this type of vaccines needs adjuvants and
repeated vaccination (Figure 4). Molecular adjuvants such as ligands of
several receptors of the innate immunity system can be used in combi-
nation with SU vaccines. One study shows that the recombinant protein
StF2.4 × M2e produced in Escherichia coli cells, which includes flagellin
(the toll‐like receptor 5 (tLr‐5) ligand), causes immunization against a
lethal dose of the influenza virus in mice.424 | VIRUS LIKE PARTICLE (VLP) VACCINE
In recent years, VLP vaccines are under precise study as potential can-
didates for vaccination against influenza. Produced VLPs are devoid of
viral genomes which reflects high safety of these vaccines. Glycopro-
teins of these particles are not exposed to destructive fixatives, and
their membrane‐anchored state imitates the conformation of nativeFIGURE 4 Subunit vaccine. Subunit vaccination induces both innate an
as TLRs and NLRs have an important role in the production of inflamma
receptors TLR7 and NLRP3 are more important from other receptors. P
providing mucosal and systemic immunity to vaccine. Subunit vaccinatio
markers including CD80/86 and MHC II molecules results in high activviral glycoproteins. VLPs can effectively stimulate APCs especially
dendritic cells and also induce both humoral and cellular responses
as well.43-49 These vaccines are able to induce immune responses of
CD4+ T‐cells as well as cytotoxic T‐cells.48,50,51 Headless HA2 protein
expressed on VLPs can induce cross‐reactive antibody response which
is effective against heterologous influenza strains in vivo.52 Immune
responses to NA and M2 antigens of influenza are relatively low which
is due to immune dominancy of HA antigen and higher number of this
antigen on influenza virions. However, by presenting less immuno-
genic viral proteins on separate VLPs, these antigens can avoid the
immune‐dominant effect of HA and thereupon will be more immuno-
genic.53,54 In addition, VLP vaccines can become more effective by
direct incorporation of adjuvant molecules.55-58
Several surveys also have demonstrated a satisfactory safety profile
for VLP vaccines. In a blinded, randomized, placebo‐controlled trial about
safety and immunogenicity of a pandemic influenza A (H1N1) 2009 VLP
vaccine generated by recombinant baculovirus culture in Sf9 cells, partic-
ipants showed only mild local reactions with no vaccine‐related systemic
AEs and the vaccine seemed to be well‐tolerated and safe enough. This
method of VLP production is considered safer than other expression sys-
tems.59 Another clinical trial also has evaluated a VLP vaccine produced
by the same method and side effects were mostly mild. However,
adjuvanted VLP vaccine could raise local and systemic reactions.60 Also,
a phase I clinical trial on previously healthy non‐immune adults exhibited
remarkable safety results for a bacterially produced VLP vaccine (gH1‐
Qbeta). Most of the reported local and systemic AEs were mild in sever-
ity and no serious AEs were occurred.615 | INFLUENZA DNA VACCINE
Although conventional influenza vaccines in preventing seasonal influ-
enza viruses are successful, they have some of the problems includingd adaptive immune response. Innate immune system receptors such
tory cytokines significantly IL6 after subunit vaccination. Among this
roduction of antibodies such as IgA, IgM, and IgG is important in
n can induce both T CD4+ and T CD8+ cells. Expression of APC
ation of these cells and increased antigen presentation by APCs.
6 of 13 KESHAVARZ ET AL.allergic reactions and strain‐specific in some patients. Therefore, the
current influenza vaccines need to be reformulated every year to act
efficient against sudden epidemics and pandemics. The production
process of a conventional influenza vaccine is time‐consuming and
so the need to design newer vaccines is of utmost importance. To
solve the disadvantages of conventional influenza vaccines, DNA
influenza vaccines are a promising approach. These vaccines are able
to induce humoral and cellular immune responses via incorporating a
gene encoding an antigen, in transfected host cells. Actually, DNA
vaccines unlike protein base vaccines can provide anti‐influenza
T‐cell‐mediated protection.62-64
Since DNA vaccine are egg‐free and can be produced more
expeditiously, thus reducing the delay from vaccine production to
clinical use and can be produced rapidly in response to epidemics or
pandemics. One of the concerns about the use of DNA vaccines is
possible risk of integration into the human genome but that
advantages make it pave for human application. Bacterial plasmids,
recombinant viral vectors, and bacterial vectors are existing DNA‐
based antigen delivery platforms which are used for DNA vaccines
manufacturing.65,66
It has been shown that intranasal DNA vaccination induces
potent mucosal and systemic immune responses and cross‐protective
immunity against influenza viruses (Figure 5). New strategies for stim-
ulation of nasal immune response have been reported with PEI/DNA
complexes. Polyethylenimine (PEI), a synthetic polycation, was previ-
ously shown to improve the efficacy of gene delivery both in vitro
and in vivo.67,68
In recent reports, adaptor molecules in TLR signaling pathway
such as MyD88 (myeloid differentiation primary response gene) and
TRIF (Toll/IL‐1 receptor (TIR)‐domain‐containing adaptor inducing
interferon‐β) were incorporated into plasmid DNA as genetic adju-
vants and improved humoral immune responses against plasmid‐
encoded antigen.69 These studies suggest that TLR agonists may act
as DNA vaccine adjuvants. Flagellin, as aTLR5 agonist, activates innate
immune responses. Dermal injection of plasmids encoding flagellin and
influenza A virus nucleoprotein results in both humoral and cellular
immune responses. The flagellin vaccine adjuvant induces antigen‐
specific IgA production and enhances protective immunity to lethal
influenza A virus infection. These findings indicate that expression of
DNA‐encoded TLR agonists can improve the immunogenicity of
DNA vaccines.70FIGURE 5 DNA vaccine. DNA vaccines have been created in complex w
DNA/Flagellin complex, in addition to cellular immunity, stimulates TLR5 in
IRF3.7 complexes and DNA/TRIF and MYD88 complexes stimulate the B
other hand, the DNA/IRF1.7 complexes mainly stimulate the pathway of cFurthermore, IRF1, 3, and 7 are other genetic adjuvants for influ-
enza virus DNA vaccines. IRF1 genetic adjuvant strongly stimulates
humoral immune responses. Conversely, IRF3 induces stronger cellular
immune responses. Meanwhile, IRF7 genetic adjuvant enhances
both humoral and cellular immune responses.71 These findings suggest
that IRF genetic adjuvants can improve both humoral and/or cellular
immune responses. Also, constitutive active forms of IRF3 and IRF7,
as DNA vaccine adjuvants, elicit both humoral and cellular immune
responses against virus infection.72 In addition, studies showed that
DNA binding domain‐lacked IRF1 (ΔIRF1) genetic adjuvant enhanced
cellular immune responses.736 | UNIVERSAL VACCINE
Genes encoding influenza virus hemagglutinin (HA) and neuraminidase
(NA) proteins have the high mutation rate, therefore yearly vaccina-
tion against circulating seasonal influenza virus strains is of great
importance. Running research priorities include the development of a
universal influenza vaccine that could evoke humoral and cellular
responses, be safe, manufactured rapidly in large amounts, and pro-
vides long‐lasting and cross‐strain protection. Moreover, efforts are
being made to design M2e‐based or stalk‐based vaccines, since these
proteins (the type‐2 matrix protein and the stalk domain of HA,
respectively) are entirely well conserved from an evolutionary stand-
point and can elicit immune response against influenza virus.746.1 | M2e‐based vaccine
Universal influenza A vaccines focus on using highly conserved
sequences among influenza virus subtypes in order to provoke
cross‐reacting antibody responses. Major targets consist of
ectodomain of matrix protein 2 and conserved epitopes of some other
influenza proteins.75 Recombinant multimeric M2e proteins can be
incorporated with several adjuvants in order to induce specific
antibodies.76 Vaccines containing M2e antigen coupled with carrier
proteins or adjuvants are able to induce strong cross‐protection
against influenza in mice. Some reports indicate a trend towards Th1
responses after vaccination, leading to induction of cytotoxic lympho-
cytes.77,78 This proton‐selective ion channel protein of influenza virus
is required to stimulate the NLRP3 inflammasome pathway. M2ith different stimulant components that stimulate different pathways.
the innate immunity leading to TNF and NO production. DNA/
lymphocytes differentiation and specific antibody secretion. On the
ellular immunity and differentiate T lymphocytes.
KESHAVARZ ET AL. 7 of 13localization to the trans‐Golgi network is important for NLRP3 activa-
tion.79 Due to lacking its proton selectivity, the mutant influenza virus
M2 protein enables the transport of other cations (Na+ and K+),
which mediates increased IL‐1β secretion compared with the wild‐
type M2 protein.79
An acceptable safety profile has been revealed for these vaccines.
ACAM‐FLU‐A,a M2e_HBc vaccine manufactured by Sanofi Pasteur
was tested in phase I clinical trial and showed no serious side
effects.80 STF2.4xM2e, M2e vaccine with flagellin as an adjuvant,
was reported to be safe, but two high doses of the vaccine were
observed to be associated with raised levels of C‐reactive protein
(CRP).81 Another universal influenza vaccine, Multimeric‐001, was
announced to be safe in phase I/II clinical trial, and no severe AE
was reported.826.2 | Epitope base vaccine
Progression in biotechnology methods has provided the emergence
of new approaches towards rational design of vaccines. One impor-
tant approach is the use of epitopes corresponding to immuno-
genic, conserved sequences of microbial proteins. Focuses on the
minimal component of these microbial pathogens that activates
the lymphocyte in the epitope‐based approach are very important.
Short peptides with 8 to 10 amino acids truly activating T‐cells
and peptides up to 20 amino acids induce B‐cells responses. Such
conserved epitopes are found in M, NP, and even HA protein of
influenza virus.83,84 Moreover, perception of the molecular basis
of antigen recognition and human leukocyte antigen (HLA) binding
motifs has ameliorate selection of peptides predicted to bind to
human class I or class II MHC molecules. The immunological effi-
cacy of peptide‐based vaccines versus infectious diseases is very
important, and it is demonstrated in animal models and clinical
studies. The most important challenges associated with peptide vac-
cines are low immunogenicity and the need for valid and simple
assays to measure the T‐cell responses. On the other hand, the
range of production options is a distinct and notable advantage of
peptide‐based vaccines.85,867 | CYTOTOXIC
T‐LYMPHOCYTE‐ INDUCING VACCINES
Cytotoxic T lymphocytes (CTLs) have the ability to target more con-
served influenza virus proteins. Unlike antibody‐mediated responses,
this response is induced mainly by the internal viral proteins.87-89
CTL responses improve recovery and inhibit disease progression and
clearance of the virus.90 As a problem, CTL vaccines need to have an
epitope that can be recognized by all major histocompatibility complex
(MHC) subclasses. Assarsson et al showed that although epitope
recognition varied across individuals, it is possible to identify epitope
regions that are recognized by all six HLA super‐ types.91 Their
study and a study by Lee et al resulted in identification of highly
conserved epitopes in the M1, NP, and PB1 proteins from more than
17 strains across six different subtypes which are targeted by CD4
and CD8 T cells.92An immunodominant CTL vaccine epitope is likely to reduce
the extent of response in primed vaccinated subjects. Thus, epitope
choice can also alter the outcome of the response, depending on
the binding avidity of the T‐cell antigen receptors (TCRs) with the
MHC peptide.93
For a strong CD8 T‐cell response, the antigen should be proc-
essed via the MHC class I processing pathway of dendritic cells
(DCs). During infection, the viral antigen is loaded onto DCs by direct
entry of the virus or through uptake of infected cells undergoing
apoptosis.94 Hence, CTL responses during vaccination are different.
In other words, LAIV induces a strong CD8 T‐cell response, while
the conventional SU TIV is less effective than the whole‐virus vaccine
at inducing CTLs.90 Thus, taking all of these considerations is needed
in the successful design and execution of a CTL‐based vaccination
approach.8 | INFLUENZA RNA VACCINE
Owing to fewer regulatory tests and being products with invariant
base regardless of the type of pathogen, a large body of evidence
have nominated nucleic acid‐based vaccines as encouraging vaccine
candidates.95
Particularly, a great deal of effort, accompanied by technological
innovation, have enhanced qualification of mRNA, thereby promot-
ing therapeutic potential in the fields of vaccine development.96
The capability of RNA vaccines to trigger strong, protective immune
responses against a wide spectrum of pathogens has led to a large
number of studies focusing on the use of these vaccines against
influenza virus. As recently approved influenza vaccines demon-
strated variable and inadequate protection, a promising efficacy has
been shown for several more recently RNA vaccines types in pre-
clinical models.97
Several features have made mRNA vaccines superior over the
other types of vaccines. First, safety: since mRNA is a non‐infectious
and has a platform which does not integrate into the genome, there
would be no possibility for infection or mutagenesis. Additionally,
the safety of mRNA vaccines is substantially enhanced by down‐
modulation of their immunogenicity. Second, efficacy: the high
stability and translatability of mRNA are a result of a variety of modi-
fications. Rapid and efficient uptake and expression of mRNA are
guaranteed through formulating it into carrier molecules. The charac-
teristic of mRNA as a minimal genetic vector impedes the anti‐vector
immunity, allowing mRNA vaccines to be administered repeatedly.
Third, production: mRNA vaccines are capable of being produced in
a rapid, cheap, and scalable manner, mainly because of the high yields
of in vitro transcription reactions.96 As toxic chemicals are not used in
manufacturing of mRNA, there is no possibility of common risks asso-
ciated with other vaccine platforms.95 However, possible undesired
consequences such as fever can originate from the extreme induction
of type I interferons and proinflammatory cytokines, mediated by
some RNA vaccines. Also, extracellular RNA arisen from vaccine may
result in safety concerns via mediating the formation of pathological
thrombus or edema.97 Despite the good antiviral protection, mRNA
vaccines require a great amount of synthetic mRNA material, probably
8 of 13 KESHAVARZ ET AL.limiting the accessibility of vaccine in cases of epidemics and
pandemics. Owing to the greater length of constructed products,
challenges remained to be addressed in terms of the production pro-
cess and stability of the mRNA products, especially with self‐
amplifying RNA vaccines.95
There are two leading types of RNA that are recently employed as
vaccines: non‐replicating mRNA and virally derived, self‐amplifying
RNA. Containing 5′ and 3′ UTRs, non‐replicating mRNA‐based
vaccines encode the antigen of interest, while self‐amplifying
RNAs encode both the antigen and the viral replication machinery,
allowing the amplification of intracellular RNA and substantial protein
expression.968.1 | Self‐amplifying mRNA vaccines
A majority of recently used self‐amplifying mRNA (SAM) vaccines are
based upon the genome of an alphavirus genome. The full‐length RNA
with an approximate length of 9 kb can be readily yielded by in vitro
transcription (IVT) from a DNA template. Intracellular replication of
RNA which encodes antigen guarantees the highly effective antigen
production from an extremely small dose of self‐amplifying RNA vac-
cine. SAM vaccines are capable of self‐production of adjuvants, inter-
mediates of replication, and the rest of contributory motifs in their
high potency.95
dsRNA is well known as a powerful pathogen‐associated molecu-
lar pattern (PAMP), identified by pattern recognition receptors in
various cellular compartments. Robust type I interferon responses
are driven by Recognition of dsRNA‐contaminated IVT mRNA. In
addition to dsRNA contaminants, exogenously delivered single‐
stranded mRNA molecules are in turn a PAMP. Single‐stranded
oligoribonucleotides and the products of their degradation are recog-
nized by the endosomal sensors Toll‐like receptor 7 (TLR7) and
TLR8, leading to type I interferon production.96 In addition, trivalent
saRNA (small activating RNAs) vaccination could result in anti‐H1N1
and H3N2 IgG responses.97
A number of delivery formulation platforms have been explained
to enhance the RNA vaccination, including PEI‐based delivery
vehicles.95 Furthermore, a validated adjuvant strategy is TriMix,
which is formed by a combination of mRNAs encoding three
immune activator proteins: CD70, CD40 ligand (CD40L), and consti-
tutively active TLR4. TriMix mRNA prolonged the immunogenicity of
naked, unmodified, unpurified mRNA and was especially linked with
increased DC maturation and cytotoxic T lymphocyte (CTL)
responses. Substantial activation of TLR7 (mouse and human) and
TLR898 and yields of type I interferon, pro‐inflammatory cytokines,
and chemokines was demonstrated following intradermal immuniza-
tion with the RNActive vaccines. Unlike the immunization with pro-
tein, several mRNA vaccines foster potent CD8+ T cell responses,
probably through efficient presentation of endogenously produced
antigens on MHC class I molecules, besides strong CD4+ T cell
responses. Additionally, unlike DNA immunization, neutralizing anti-
body responses with much lower doses of mRNA vaccines have
been generated. Consequently, mRNA vaccines have inducedprotective immunity against various infectious agents in preclinical
models.969 | MICRORNA AND EXOSOME‐BASED
VACCINE
MicroRNAs are small non‐coding RNAs which act as epigenetic regu-
lators.99-106 These molecules play critical roles in regulation of gene
expression in the RNA and protein levels.22,107-113 It has been shown
that deregulation of microRNAs is associated with initiation and pro-
gression of various diseases such as infectious diseases, cardiovascular
diseases, diabetes, neurogenerative diseases, and cancer.112,114-134
Exosomes are other particles which have critical roles in the path-
ogenesis of various diseases.122,135-137 Exosomes are nano‐carriers
which carry many cargos such as DNAs, RNAs, microRNAs, LncRNAs,
and proteins. Targeting these cargos to host cells could lead to change
behaviors of cells and contribute to progression of physiological and
pathological processes.138,139
As vaccine preparation through classical temperature‐based
attenuation method was a time‐consuming procedure, the need for
urgent control of influenza outbreaks emerge from mutant viruses,
highlighting the importance of preparing vaccines based on other
mechanisms such as (microRNA) miRNA and exosome technolo-
gies.140 MiRNA‐based strategy for influenza virus attenuation could
act through sequence‐specific gene silencing mechanism or using
miRNA/siRNA to suppress virus replication or infection.
According to previous studies, inserting miRNA response element
(MRE) of viral microRNAs into Influenza virus genome could limit tis-
sue tropism, and incorporating miRNA target site into viral NP or HA
segment resulted to attenuate influenza A virus.99,141,142 Further, in
numerous studies, specific miRNAs have been recruited to demon-
strate which gene targeting segments have maximal potential for
viral attenuations. For example, a recent study on mice models
demonstrated that inserting of miR‐let‐7b target sequence into 2009
pandemic H1N1virus (H1N1) genome successfully produced a recom-
binant virus which was slow to grow and attenuated in mice respira-
tory system.143
Another in vivo study found that incorporating miR‐93 target sites
into H1N1 and H5N1 viruses could result in viral attenuation in
human lines and mouse lungs.141 Similarly, fusing of miR‐192 target
sequence into IAV genome could attenuate influenza pathogenicity
in mice.142 Furthermore, the ability of miRNA‐based attenuation
method to determine virus fitness through introducing various number
and location of target sites is superiority over classical viral attenua-
tion methods.144 Together, these evidences suggested that the engi-
neering flu genome virus containing the target sites of deregulated
miRNAs in a species‐specific manner could be employed as a high‐
throughput strategy which is able to provide a new class of flu IAV
vaccines. Fortunately, at the moment, a MRE design web server is
available in which users could design various number of MRE tools
for Influenza A genome to produce LAVs and help reduce experimen-
tal time and costs.145
Exosomes are two membrane‐enclosed nano‐vesicles that are
actively secreted by a variety of cells into the extracellular space.
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biologically active proteins, lipids, and various nucleic acids including
mRNA, miRNA, ribosomal RNA (rRNA), long noncoding RNA
(lncRNA), and variably some DNA.146-149 Through different studies
conducted on distinct techniques such as stem‐loop PCR and
microfluidic microarray, it was found that more than 274 miRNAs were
secreted by different cell types via exosomes.150,151 The secretion of
miRNAs through exosomes in the extracellular fluids guarantees their
half time and keeps them away from degradation by body fluid
enzymes.148,150,151 Based on previous studies, exosome‐mediated
extracellular delivery also exists in viral life cycles. Transition of viral
components including viral mRNA, miRNA, and genomic RNA, as well
as genetic regulatory through exosomes, increased viral persistence,
skipping host immune system and spread to uninfected cells.146 These
findings are promising that an expressional exosomal miRNA could be
used in therapeutic and diagnostic fields. However, exosomes which
are produced naturally in tissues are not filled with a great amount of
proteins or miRNAs; therefore, to prepare more efficient targeted
delivery exosomes, it is crucial to develop an efficient purification
method to enrich specific miRNA in isolated exosome.
In two recent studies,152,153 exosomes were enriched with a
selected miRNA using a modified calcium‐chloride mediated or elec-
troporation. The results show these exosomes as cargo could success-
fully deliver a great deal of miRNA mimic(s) or inhibitor(s) to the target
cells and lead to overexpression or deletion of the designed miRNA in
recipient cells as well as alter cellular function.
These findings suggested that engineered exosomes as natural
vehicles could represent a powerful tool for targeted delivery. Hence,
exosomes could be clinically suitable applications for enhancing
patient condition. Despite these advances, it seems there are still
many challenges ahead, and existing techniques in exosome‐mediated
drug delivery need further development.10 | CONCLUSION
In conclusion, most studies indicate that each type of influenza vac-
cines has particular excellences compared with another. For example,
LAIV and VLP vaccines in addition to induction of antibody responses
are able to stimulate effective cellular immune responses and in this
respect are better than inactivated vaccines. However, newer vaccines
such as VLPs can be more advanced and effective choices for exten-
sive immunization of different populations. Influenza vaccines also
can cause various inevitable adverse effects which for some vaccines
with more severe local and systemic side effects may lead to uncer-
tainty for clinical applications. Up to now among available influenza
vaccines, emerging VLP vaccines seem to have the lowest reported
AEs, although universal utilization of these vaccines needs more
comprehensive clinical surveys. Overall, if advantages can overcome
disadvantages, a vaccine will be suitable for immunization programs.
Future studies can offer more ideal products by assembling the advan-
tages of existing vaccines in a unique influenza vaccine.
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